Telix Pharmaceuticals (ASX:TLX) reports on its March Quarter

Company News

by Lauren Evans

Telix Pharmaceuticals (ASX:TLX) reported on its March quarter, with focus placed on its prostate cancer product. 

The company held cash reserves of $154.7 million, compared to $22 million the prior quarter thanks to a $175 million placement earlier this year to fund projects. Its net operating outflows during the quarter were $33.6 million, with total operating outflows of $36.7 million.

Telix said the commercial launch in the US of its prostate cancer imaging product, Illuccix® was a major area of focus during the quarter and was available in 117 commercial nuclear pharmacies. Telix confirmed its plans to launch in Australia in the June quarter.

“This has been a pivotal quarter for Telix, as we delivered on several major objectives including the Company transformational event of launching of our first commercial product and completion of target enrolment for a Phase III clinical trial," said chief executive officer Christian Behrenbruch. 

"The recent financing activity – including the $175.0 million placement and $18.2 million project financing package for the buildout of the Company’s European manufacturing site will support Telix’s growth trajectory as a market leader in the field of radiopharmaceuticals."

Shares in Telix Pharmaceuticals (ASX:TLX) are trading 1.5 per cent lower at $4.53. 
 
Image from: https://telixpharma.com/our-technology/

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.